EVO - Evotec SE - ADR
IEX Last Trade
3.76
0.050 1.330%
Share volume: 41,510
Last Updated: Fri 30 Aug 2024 09:55:25 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$3.71
0.05
1.35%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
12.54%
1 Month
-19.96%
3 Months
-16.59%
6 Months
-49.67%
1 Year
-68.64%
2 Year
-66.64%
Key data
Stock price
$3.76
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.85 - $12.40
52 WEEK CHANGE
-$0.68
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Werner Lanthaler
Region: US
Website: https://www.evotec.com/
Employees: 4,200
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.evotec.com/
Employees: 4,200
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.
Recent news